Program
NWRD09
A development code. Also written as “NWRD09 administered by intramuscular injection”, “NWRD09 Injection” and “NWRD09 injection”.
Its studies are mostly in Squamous Intraepithelial Lesions · Carcinoma in Situ, led by Newish Biotech (Wuxi).
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Newish Biotech (Wuxi) | 66 open or running | phase 2since Apr 10, 2026 | Dec 16, 2024 | Dec 30, 2026phase 1 · NCT07710664 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 16, 2024First study: no phase study in Carcinoma in SituFirst studyNCT06741150 · 18 planned · China
- Jun 24, 2025Phase 1 study in Squamous Intraepithelial LesionsNCT07047989 · 9 planned · China
- Jul 21, 2025No phase study in Carcinoma in SituNCT07092007 · 18 planned · China
- Apr 10, 2026Phase 2 study in Persistent HPV16 InfectionPhase 2 reachedNCT07536282 · 78 planned · United States
- Jul 8, 2026Phase 2 study in Squamous Intraepithelial LesionsNCT07712692 · 156 planned · China
- Jul 13, 2026Phase 1 study in Persistent HPV16 InfectionNCT07710664 · 10 planned · China
Ahead
- Dec 30, 2026Primary completion: phase 1 study in Persistent HPV16 InfectionNCT07710664
- Jun 30, 2027Primary completion: phase 2 study in Squamous Intraepithelial LesionsNCT07712692
- Sep 2027Primary completion: phase 2 study in Persistent HPV16 InfectionNCT07536282
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07710664Persistent HPV16 Infection · China | 1 | Recruiting | Dec 30, 2026 | 10 |
| NCT07712692Squamous Intraepithelial Lesions · China | 2 | Not yet recruiting | Jun 30, 2027 | 156 |
| NCT07536282Persistent HPV16 Infection · United States | 2 | Not yet recruiting | Sep 2027 | 78 |
| NCT07092007Carcinoma in Situ · China | – | Recruiting | Dec 31, 2025 | 18 |
| NCT07047989Squamous Intraepithelial Lesions · China | 1 | Recruiting | Jul 31, 2026 | 9 |
| NCT06741150Carcinoma in Situ · China | – | Recruiting | Dec 31, 2025 | 18 |
How it is read
Names in the registry
- “NWRD09”, 2 entries
- “NWRD09 administered by intramuscular injection”, 2 entries
- “NWRD09 Injection”, 1 entry
- “NWRD09 injection”, 1 entry
Codes read as this program: NWRD09.
Conditions, from the studies’ own filings
- Squamous Intraepithelial Lesions, 2 studies
- Carcinoma in Situ, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.